A Good Week for Our Members and an Upcoming Report on a NASDAQ Biopharma Company with a Solid Pipeline to be Issued Tomorrow 12-08-21 Near Market Open.

A Good Week for Our Members and an Upcoming Report on a NASDAQ Biopharma Company with a Solid Pipeline to be Issued Tomorrow 12-08-21 Near Market Open.

Good day everyone,

I want to talk about a couple of our recent reports, Citius Pharmaceuticals (CTXR) and Siyata Mobile (SYTA). We alerted CTXR on Monday of this week at $1.51/share, announcing that the company had two phase three trials drawing to a conclusion. Today, on our second day of coverage the company shares hit a high of $1.87 for a potential gain of 23.8% for our members. I still believe CTXR has more traction and will go higher in the near to mid-term

We alerted SYTA at the beginning of last week at a price of $3.42/share. We thought the news about their two new products and a partnership with Motorola (MSI) was a real catalyst, but the shares went nowhere during our coverage. Perhaps you heard already, buy SYTA spent most of today as the top gainer on the NASDAQ, reaching a high of $7.20/share on news they had already gotten $1.8M in purchase orders for the new products we talked about. The move represents a potential 110% gain for our members.

We hope some of you got a benefit from those two reports.

It seems like the major stock indices are taking a turn in the right direction. As I’m writing this, the DJIA is up 1.49% and the NASDAQ is up 2.96%. Maybe investors are feeling a bit more confident this week. I want to remind all our members that the Fed is meeting in a week to discuss any potential moves to rein in the current level of inflation. You can bet that Wall Street will be watching closely.

I want to report on a NASDAQ biopharma company that I think offers a fantastic opportunity for a near term gain. When you review their pipeline in development you may agree with me that there are some solid product candidates included, with catalyst potential.

This company has a small share structure along with a good level of insider and institutional ownership. Their recent financial statement looks strong for a development stage biopharma company. One of the things I like about this company is that they are developing products in major biopharma market sectors.

Stay tuned and stay informed.

The Traders News Group